Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

KPTIQKaryopharm Therapeutics Inc.

OTC · CIK 0001503802
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts321

Identity from submissions API

NameKaryopharm Therapeutics Inc.
CIK0001503802
TickersKPTIQ, KPTI
Exchanges, Nasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN263931704
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone617-658-0600
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
85 WELLS AVENUE
SECOND FLOOR
NEWTON
MA
02459
MA
Mailing address
85 WELLS AVENUE
SECOND FLOOR
NEWTON
MA
02459
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

1157 filing rows loaded from submissions recent; extra archives: CIK0001503802-submissions-001.json (156 filings, 2010-11-05 to 2015-04-05).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001346824-26-000285 005-87705 261562790 34 15414
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001011438-26-000695 005-87705 261552709 34 10680
2026-11-13 NT 10-Q NT 10-Q 0001193125-26-460615 001-36167 261552435 34 31248
2026-11-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-007570 005-87705 261543934 34 13201
2026-11-09 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000886982-26-000549 005-87705 261535200 34 18434
2026-11-05 8-K 8-K 3.01 0001193125-26-448516 001-36167 261524645 34 147316 1 1
2026-11-03 8-K 8-K 1.01,1.03,2.03,2.04,7.01,8.01,9.01 0001193125-26-444164 001-36167 261514188 34 2716136 1 1
2026-11-02 8-K 8-K 7.01,9.01 0001193125-26-442822 001-36167 261510167 34 167937 1 1
2026-10-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-119710 005-87705 261496812 34 19481
2026-10-22 8-K 8-K 8.01 0001193125-26-428938 001-36167 261479044 34 137252 1 1
2026-10-19 4 4 0001193125-26-425227 5018
2026-10-14 8-K 8-K 8.01 0001193125-26-421025 001-36167 261458278 34 136982 1 1
2026-10-08 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001636587-26-000086 005-87705 261448637 34 12520
2026-10-02 4 4 0001193125-26-412209 5016
2026-09-25 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001636587-26-000084 005-87705 261409544 34 12520
2026-09-25 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001636587-26-000083 005-87705 261407147 34 12515
2026-09-18 8-K 8-K 3.03,5.03,9.01 0001193125-26-395517 001-36167 261390849 34 656108 1 1
2026-09-11 8-K 8-K 1.01,2.04,3.02,8.01,9.01 0001193125-26-388621 001-36167 261372688 34 564519 1 1
2026-09-04 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-105556 005-87705 261362928 34 18720
2026-09-02 4 4 0001193125-26-380404 5015
2026-08-31 8-K 8-K 8.01 0001193125-26-375495 001-36167 261342605 34 145572 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-000925 005-87705 261283055 34 15498
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001831942-26-000037 005-87705 261281777 34 14095
2026-08-13 10-Q 10-Q 0001193125-26-347906 001-36167 261270090 34 12185166 1 1
2026-08-13 8-K 8-K 2.02,9.01 0001193125-26-347897 001-36167 261270083 34 535609 1 1
2026-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-004964 005-87705 261266223 34 13108
2026-08-11 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000886982-26-000401 005-87705 261265034 34 18361
2026-07-31 8-K 8-K 8.01 0001193125-26-326995 001-36167 261225546 34 152475 1 1
2026-07-30 4 4 0001193125-26-326290 4979
2026-07-28 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002546 005-87705 261212582 34 10801
2026-07-17 8-K 8-K 5.02 0001193125-26-307964 001-36167 261184400 34 139116 1 1
2026-06-05 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001897612-26-000511 005-87705 261067626 34 7684
2026-05-28 8-K 8-K 5.02,5.07,9.01 0001503802-26-000027 001-36167 261035950 34 233292 1 1
2026-05-27 S-8 S-8 0001193125-26-242089 333-296281 261027293 33 179916 1 1
2026-05-27 S-8 S-8 0001193125-26-242083 333-296280 261027266 33 185278 1 1
2026-05-26 4 4 0001822092-26-000004 5034
2026-05-26 4 4 0001270734-26-000002 5063
2026-05-26 4 4 0001340875-26-000005 5050
2026-05-26 4 4 0001991642-26-000002 5007
2026-05-26 4 4 0001254705-26-000008 5273
2026-05-26 4 4 0001291963-26-000004 5282
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-227136 005-87705 26989424 34 152772
2026-05-15 4 4 0001193125-26-226697 6932
2026-05-15 4 4 0001193125-26-226685 6994
2026-05-15 4 4 0001193125-26-226652 6843
2026-05-15 4 4 0001193125-26-226616 7207
2026-05-15 4 4 0001193125-26-226613 6932
2026-05-15 4 4 0001193125-26-226604 6941
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001636587-26-000031 005-87705 26985988 34 12518
2026-05-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001656 333-295535 26981806 33 1757
2026-05-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001655 333-295533 26981804 33 1757
2026-05-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001011438-26-000310 005-87705 26978768 34 10123
2026-05-14 10-Q 10-Q 0001193125-26-222827 001-36167 26975884 34 10979914 1 1
2026-05-14 8-K 8-K 2.02,9.01 0001193125-26-222808 001-36167 26975861 34 473361 1 1
2026-05-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-002939 005-87705 26971301 34 16939
2026-05-12 CORRESP filename1.htm 0001193125-26-219351 6423
2026-05-12 CORRESP filename1.htm 0001193125-26-219339 6423
2026-05-12 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000886982-26-000235 005-87705 26968232 34 18167
2026-05-11 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-022238 005-87705 26963541 34 22962
2026-05-07 UPLOAD filename1.pdf 0000000000-26-004695 333-295535 147902
2026-05-07 UPLOAD filename1.pdf 0000000000-26-004694 333-295533 147900
2026-05-04 S-3 S-3 0001193125-26-204134 333-295535 26938409 33 893482 1 1
2026-05-04 S-3 S-3 0001193125-26-204130 333-295533 26938385 33 1591162 1 1
2026-04-22 4 4 0001825322-26-000006 5040
2026-04-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-042704 005-87705 26858628 34 18309
2026-04-13 ARS ARS 0001503802-26-000024 001-36167 26856532 34 2514289
2026-04-13 DEF 14A DEF 14A 0001503802-26-000023 001-36167 26856528 34 5991328 1 1
2026-04-02 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001346824-26-000092 005-87705 26834718 34 19976
2026-04-02 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001831942-26-000015 005-87705 26834107 34 15009
2026-03-27 8-K 8-K 8.01 0001503802-26-000011 001-36167 26801151 34 173864 1 1
2026-03-24 8-K 8-K 1.01,3.02,7.01,8.01,9.01 0001193125-26-120770 001-36167 26784224 34 10110148 1 1
2026-03-03 4 4 0002045943-26-000003 4880
2026-03-03 4 4 0001837741-26-000003 4853
2026-03-03 4 4 0001865796-26-000003 4906
2026-03-03 4 4 0001825322-26-000003 4906
2026-03-03 4 4 0001804460-26-000003 4842
2026-03-03 4 4 0001942597-26-000003 4844
2026-03-03 8-K 8-K 1.01,8.01,9.01 0001503802-26-000006 001-36167 26709892 34 395592 1 1
2026-02-19 8-K 8-K 5.07 0001193125-26-059349 001-36167 26654359 34 189452 1 1
2026-02-19 4 4 0001193125-26-059332 4841
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001897612-26-000267 005-87705 26637788 34 7571
2026-02-13 10-K 10-K 0001193125-26-049397 001-36167 26628442 34 20956478 1 1
2026-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-000896 005-87705 26623665 34 13023
2026-02-12 8-K 8-K 2.02,9.01 0001193125-26-047670 001-36167 26623431 34 550972 1 1
2026-02-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-012689 005-87705 26616793 34 18146
2026-02-09 4 4 0001193125-26-042799 4825
2026-02-04 4 4 0001193125-26-037584 4894
2026-02-03 4 4 0001193125-26-035687 4891
2026-02-03 4 4 0001193125-26-035682 4917
2026-02-03 4 4 0001193125-26-035663 4876
2026-02-03 4 4 0001193125-26-035661 4838
2026-02-03 4 4 0001193125-26-035655 4829
2026-01-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001315863-26-000103 005-87705 26580221 34 16552
2026-01-29 4 4 0001193125-26-029599 6798
2026-01-22 4 4 0001193125-26-019428 4878
2026-01-12 8-K 8-K 2.02,8.01,9.01 0001193125-26-009738 001-36167 26524628 34 314102 1 1
2026-01-09 DEF 14A DEF 14A 0001193125-26-008939 001-36167 26523253 34 4354308
2025-12-30 PRE 14A PRE 14A 0001193125-25-337113 001-36167 251614426 34 4355031
2025-11-24 424B3 424B3 0001193125-25-291933 333-291223 251509497 33 332541
2025-11-24 424B3 424B3 0001193125-25-291930 333-291224 251509490 33 299498
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-004954 005-87705 251482556 34 10646
2025-11-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001897612-25-000507 005-87705 251461662 34 7570
2025-11-03 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-25-020601 005-87705 251444570 34 9634
2025-11-03 S-3 S-3 0001193125-25-262581 333-291224 251444298 33 520038 1 1
2025-11-03 S-3 S-3 0001193125-25-262571 333-291223 251444240 33 557802 1 1
2025-11-03 10-Q 10-Q 0001193125-25-261667 001-36167 251442100 34 12007220 1 1
2025-11-03 8-K 8-K 2.02,9.01 0001193125-25-261663 001-36167 251442092 34 518649 1 1
2025-10-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-25-000154 005-87705 251434813 34 6198
2025-10-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-25-018449 005-87705 251400824 34 23795
2025-10-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000019617-25-001004 005-87705 251400033 34 7251
2025-10-16 4 4 0001193125-25-241487 4906
2025-10-16 4 4 0001193125-25-241484 4760
2025-10-16 4 4 0001193125-25-241479 4781
2025-10-16 4 4 0001193125-25-241471 4757
2025-10-16 4 4 0001193125-25-241468 4821
2025-10-16 4 4 0001193125-25-241461 5011
2025-10-14 8-K 8-K 1.01,2.03,8.01,9.01 0001193125-25-239015 001-36167 251391854 34 6556591 1 1
2025-10-08 8-K 8-K 1.01,2.02,2.03,3.02,5.02,7.01,8.01,9.01 0001193125-25-233983 001-36167 251381219 34 282630 1 1
2025-10-03 4 4 0001193125-25-230359 5304
2025-09-16 4 4 0001193125-25-205052 6801
2025-09-16 4 4 0001193125-25-205049 6823
2025-09-16 4 4 0001193125-25-205046 6802
2025-09-16 4 4 0001193125-25-205044 6864
2025-09-16 4 4 0001193125-25-205042 7110
2025-09-16 4 4 0001193125-25-205038 7084
2025-09-11 8-K 8-K 5.02 0001503802-25-000006 001-36167 251308940 34 178844 1 1
2025-09-04 4 4 0002045943-25-000004 4877
2025-08-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001897612-25-000365 005-87705 251216254 34 9213
2025-08-11 S-8 S-8 0001193125-25-177472 333-289466 251200251 33 177061 1 1
2025-08-11 10-Q 10-Q 0000950170-25-106238 001-36167 251200197 34 11258231 1 1
2025-08-11 8-K 8-K 2.02,9.01 0000950170-25-106236 001-36167 251200194 34 487174 1 1
2025-07-30 4 4 0000950170-25-100373 4842
2025-07-23 4 4 0000950170-25-097965 4877
2025-07-16 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000019617-25-000528 005-87705 251126321 34 6618
2025-07-11 8-K 8-K 7.01,9.01 0000950170-25-095167 001-36167 251117501 34 29521706 1 1
2025-05-29 8-K 8-K 5.02,5.07,9.01 0000950170-25-079009 001-36167 251003851 34 224966 1 1
2025-05-29 4 4 0000950170-25-078974 5419
2025-05-29 4 4 0000950170-25-078961 5475
2025-05-29 4 4 0000950170-25-078956 5446
2025-05-29 4 4 0000950170-25-078950 5473
2025-05-29 4 4 0000950170-25-078944 5461
2025-05-29 4 4 0000950170-25-078938 5458
2025-05-29 4 4 0000950170-25-078937 5463
2025-05-12 10-Q 10-Q 0000950170-25-069231 001-36167 25935012 34 9271898 1 1
2025-05-12 8-K 8-K 2.02,9.01 0000950170-25-069176 001-36167 25934778 34 445301 1 1
2025-05-07 4 4 0000950170-25-065884 4836
2025-04-24 4 4 0000950170-25-058137 4889
2025-04-14 ARS ARS 0000950170-25-053516 001-36167 25834271 34 1461430
2025-04-14 DEFA14A DEFA14A 0000950170-25-053514 001-36167 25834267 34 1404320
2025-04-14 DEF 14A DEF 14A 0000950170-25-053511 001-36167 25834263 34 18072259 1 1
2025-04-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001999371-25-004117 005-87705 25829293 34 9983
2025-04-07 4 4 0000950170-25-051658 5278
2025-03-06 4 4 0000950170-25-034743 5351
2025-03-06 4 4 0000950170-25-034736 5287
2025-03-06 4 4 0000950170-25-034732 5339
2025-03-06 4 4 0000950170-25-034723 5290
2025-03-06 4 4 0000950170-25-034662 5325
2025-03-06 4 4 0000950170-25-034650 5311
2025-03-04 4 4 0000950170-25-032323 11769
2025-03-04 4 4 0000950170-25-032315 11530
2025-03-04 4 4 0000950170-25-032309 11482
2025-03-04 4 4 0000950170-25-032305 7600
2025-03-04 4 4 0000950170-25-032297 7563
2025-03-04 4 4 0000950170-25-032280 11500
2025-02-24 8-K 8-K 3.03,5.03,9.01 0000950170-25-025640 001-36167 25657216 34 206557 1 1
2025-02-19 4 4 0000950170-25-023192 4849
2025-02-19 10-K 10-K 0000950170-25-022765 001-36167 25637194 34 19441290 1 1
2025-02-19 8-K 8-K 2.02,9.01 0000950170-25-022764 001-36167 25637185 34 521460 1 1
2025-02-12 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000871 005-87705 25612654 34 16249
2025-02-05 4 4 0000950170-25-014491 4846
2025-02-03 4 4 0000950170-25-012326 7161
2025-01-31 8-K 8-K 5.02 0001193125-25-018385 001-36167 25578379 34 146107 1 1
2025-01-30 8-K 8-K 5.07 0001193125-25-017223 001-36167 25573695 34 154485 1 1
2025-01-13 8-K 8-K 2.02,9.01 0000950170-25-004591 001-36167 25524987 34 295938 1 1
2025-01-07 4 4 0000950170-25-002819 4847
2025-01-06 3 3 0000950170-25-002284 11338
2025-01-02 8-K 8-K 5.02,9.01 0000950170-25-000092 001-36167 25500213 34 255001 1 1
2024-12-16 DEF 14A DEF 14A 0000950170-24-136598 001-36167 241551726 34 1686660
2024-12-05 PRE 14A PRE 14A 0000950170-24-133728 001-36167 241529571 34 1692989
2024-12-05 4 4 0000950170-24-133689 4847
2024-12-03 8-K 8-K 7.01,9.01 0001193125-24-269398 001-36167 241521054 34 191807 1 1
2024-11-22 3 3 0000950170-24-130174 12014
2024-11-20 8-K 8-K 5.02 0001193125-24-262541 001-36167 241480482 34 146511 1 1
2024-11-14 SC 13G/A d11530516_13g-a.htm 0000919574-24-006742 005-87705 241462817 34 178693
2024-11-12 SC 13G/A UnitedStates_13G__Karyopharm.txt 0000932471-24-001032 005-87705 241447581 34 6550
2024-11-08 8-K 8-K 1.01,9.01 0000950170-24-124067 001-36167 241440481 34 275644 1 1
2024-11-06 4 4 0000950170-24-122274 5295
2024-11-05 S-8 S-8 0001193125-24-250994 333-282994 241425709 33 71966
2024-11-05 10-Q 10-Q 0000950170-24-121076 001-36167 241425674 34 9609711 1 1
2024-11-05 8-K 8-K 2.02,9.01 0001193125-24-250984 001-36167 241425648 34 280681 1 1
2024-11-04 SC 13G/A UnitedStates_13G__Karyopharm.txt 0000932471-24-000431 005-87705 241421703 34 5612
2024-10-31 8-K 8-K 7.01,8.01,9.01 0001193125-24-248162 001-36167 241412471 34 202636 1 1
2024-10-25 SC 13G KARYOPHARM THERAPEUTICS INC. 0000902664-24-005987 005-87705 241394931 34 50081
2024-10-07 4 4 0000950170-24-113263 4849
2024-09-17 8-K 8-K 3.01 0001193125-24-220534 001-36167 241304346 34 147630 1 1
2024-09-05 4 4 0000950170-24-104038 4873
2024-09-05 4 4 0000950170-24-104033 4849
2024-09-05 4 4 0000950170-24-104031 4846
2024-09-05 4 4 0000950170-24-103998 5139
2024-08-29 8-K 8-K 5.02,9.01 0001193125-24-209907 001-36167 241263624 34 298733 1 1
2024-08-08 4 4 0000950170-24-094087 4849
2024-08-06 10-Q 10-Q 0000950170-24-091210 001-36167 241177138 34 9730552 1 1
2024-08-06 8-K 8-K 2.02,9.01 0001193125-24-194427 001-36167 241177117 34 292583 1 1
2024-07-31 4 4 0000950170-24-088589 4851
2024-07-19 SC TO-I/A SC TO-I/A 0001193125-24-181634 005-87705 241127873 34 16526
2024-07-09 4 4 0000950170-24-082417 4849
2024-07-08 SC 13G/A us48576u1060_070824.txt 0001086364-24-008142 005-87705 241105125 34 12869
2024-06-20 SC TO-I SC TO-I 0001193125-24-164000 005-87705 241054118 34 7208955
2024-06-07 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-06-07 16:30:00 9999999995-24-001788 333-279833 241031373 33 1765
2024-06-07 4 4 0000950170-24-070991 15119
2024-06-06 4 4 0000950170-24-069860 4845
2024-06-06 4 4 0000950170-24-069856 4849
2024-06-05 CORRESP filename1.htm 0001193125-24-154766 6175
2024-06-04 4 4 0000950170-24-068969 15130
2024-06-03 UPLOAD filename1.pdf 0000000000-24-006340 333-279833 40313
2024-05-31 8-K 8-K 5.02,5.07,9.01 0001193125-24-151049 001-36167 241007744 34 168794 1 1
2024-05-30 4 4 0000950170-24-066787 5103
2024-05-30 4 4 0000950170-24-066786 5142
2024-05-30 4 4 0000950170-24-066785 5160
2024-05-30 4 4 0000950170-24-066784 5130
2024-05-30 4 4 0000950170-24-066782 5157
2024-05-30 4 4 0000950170-24-066781 5145
2024-05-30 4 4 0000950170-24-066771 5147
2024-05-30 S-3 S-3 0001193125-24-150438 333-279833 241006176 33 312497
2024-05-30 S-8 S-8 0001193125-24-150328 333-279823 241005226 33 71321
2024-05-23 SC 13G formsc13g.htm 0001493152-24-021156 005-87705 24978747 34 113588
2024-05-14 8-K 8-K 8.01,9.01 0001193125-24-138211 001-36167 24944261 34 4837050 1 1
2024-05-08 10-Q 10-Q 0000950170-24-055672 001-36167 24926227 34 7376753 1 1
2024-05-08 8-K 8-K 1.01,2.03,3.02,7.01,9.01 0001193125-24-133791 001-36167 24924285 34 223666 1 1
2024-05-08 8-K 8-K 2.02,9.01 0001193125-24-133784 001-36167 24924276 34 254196 1 1
2024-05-07 4 4 0000950170-24-054686 4846
2024-04-23 4 4 0000950170-24-046871 4898
2024-04-19 ARS ARS 0001193125-24-101705 001-36167 24855643 34 2838232
2024-04-19 DEFA14A DEFA14A 0000950170-24-045718 001-36167 24855635 34 1451592
2024-04-19 DEF 14A DEF 14A 0000950170-24-045717 001-36167 24855627 34 7283256 1 1
2024-04-18 UPLOAD filename1.pdf 0000000000-24-004255 001-36167 39772
2024-04-08 SC TO-C SC TO-C 0001193125-24-089714 005-87705 24830406 34 28140
2024-04-08 PRE 14A PRE 14A 0000950170-24-042645 001-36167 24830098 34 6428586 1 1
2024-04-05 4 4 0000950170-24-042350 4846
2024-04-03 CORRESP filename1.htm 0001193125-24-086060 62544
2024-03-21 UPLOAD filename1.pdf 0000000000-24-003085 001-36167 43210
2024-03-06 4 4 0000950170-24-027153 5288
2024-03-04 4 4 0000950170-24-025193 7151
2024-03-04 4 4 0000950170-24-025192 7101
2024-03-04 4 4 0000950170-24-025191 7096
2024-03-04 4 4 0000950170-24-025190 7122
2024-03-04 4 4 0000950170-24-025189 7162
2024-03-04 4 4 0000950170-24-025188 7101
2024-02-29 4 4 0000950170-24-023297 4854
2024-02-29 4 4 0000950170-24-023293 4806
2024-02-29 4 4 0000950170-24-023292 6591
2024-02-29 4 4 0000950170-24-023290 4827
2024-02-29 4 4 0000950170-24-023285 4867
2024-02-29 4 4 0000950170-24-023281 4802
2024-02-29 10-K 10-K 0000950170-24-022650 001-36167 24698907 34 16853272 1 1
2024-02-29 8-K 8-K 2.02,9.01 0001193125-24-051845 001-36167 24698897 34 280122 1 1
2024-02-20 4 4 0000950170-24-017237 6249
2024-02-20 8-K 8-K 8.01 0001193125-24-039387 001-36167 24650798 34 144368 1 1
2024-02-14 SC 13G/A karypharm.htm 0001306923-24-000004 005-87705 24639837 34 12003
2024-02-14 SC 13G/A d10982472_13g-a.htm 0000919574-24-001291 005-87705 24633802 34 218849
2024-02-13 SC 13G SCHEDULE 13G 0001104659-24-021272 005-87705 24628737 34 13043
2024-02-12 SC 13G/A SC 13G/A 0001104659-24-013556 005-87705 24617225 34 77153
2024-02-08 4 4 0000950170-24-012832 4845
2024-02-08 4 4 0000950170-24-012824 4847
2024-01-25 4 4 0000950170-24-007621 5361
2024-01-25 4 4 0000950170-24-007614 5119
2024-01-25 4 4 0000950170-24-007610 5071
2024-01-25 4 4 0000950170-24-007589 5091
2024-01-25 4 4 0000950170-24-007588 5064
2024-01-25 4 4 0000950170-24-007583 5066
2024-01-25 SC 13G/A us48576u1060_012524.txt 0001086364-24-003344 005-87705 24561129 34 13465
2024-01-22 SC 13G/A Karyopharm_Th_Inc.txt 0000093751-24-000068 005-87705 24548056 34 8462
2024-01-08 4 4 0000950170-24-003177 4845
2024-01-08 8-K 8-K 2.02,9.01 0001193125-24-003978 001-36167 24518547 34 224260 1 1
2023-12-12 8-K 8-K 3.01 0001193125-23-293373 001-36167 231481282 34 146920 1 1
2023-12-08 8-K 8-K 5.02 0001193125-23-291208 001-36167 231473956 34 141428 1 1
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057465 4994
2023-11-07 4 FORM 4 SUBMISSION 0001209191-23-054626 4996
2023-11-02 10-Q 10-Q 0000950170-23-057754 001-36167 231370143 34 8998859 1 1
2023-11-02 8-K 8-K 2.02,9.01 0001193125-23-268840 001-36167 231370110 34 288709 1 1
2023-10-05 4 FORM 4 SUBMISSION 0001209191-23-052215 4994
2023-09-12 4 4 0000950170-23-047712 4780
2023-09-06 4 4 0000950170-23-046721 6169
2023-09-05 4 FORM 4 SUBMISSION 0001209191-23-048162 4993
2023-09-05 4 FORM 4 SUBMISSION 0001209191-23-048161 5020
2023-09-05 4 FORM 4 SUBMISSION 0001209191-23-048159 5060
2023-09-01 4 FORM 4 SUBMISSION 0001209191-23-047913 5420
2023-09-01 3 FORM 3 SUBMISSION 0001209191-23-047912 7128
2023-09-01 8-K 8-K 5.02 0001193125-23-226903 001-36167 231230661 34 147355 1 1
2023-08-08 4 FORM 4 SUBMISSION 0001209191-23-045045 4994
2023-08-02 S-8 S-8 0001193125-23-201207 333-273593 231133882 33 79001
2023-08-02 10-Q 10-Q 0000950170-23-036780 001-36167 231133750 34 10712026 1 1
2023-08-02 8-K 8-K 2.02,9.01 0001193125-23-201161 001-36167 231133741 34 283431 1 1
2023-08-01 4 FORM 4 SUBMISSION 0001209191-23-044040 4997
2023-07-10 SC 13G/A Karyopharm_Thera_Inc.txt 0000093751-23-000633 005-87705 231079400 34 8359
2023-07-06 4 FORM 4 SUBMISSION 0001209191-23-041635 4994
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036248 5260
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035057 5438
2023-06-05 4 FORM 4 SUBMISSION 0001209191-23-034262 4989
2023-05-25 4 FORM 4 SUBMISSION 0001209191-23-032152 5290
2023-05-25 4 FORM 4 SUBMISSION 0001209191-23-032149 5308
2023-05-25 4 FORM 4 SUBMISSION 0001209191-23-032146 5278
2023-05-25 4 FORM 4 SUBMISSION 0001209191-23-032144 5305
2023-05-25 4 FORM 4 SUBMISSION 0001209191-23-032140 5264
2023-05-25 4 FORM 4 SUBMISSION 0001209191-23-032138 5295
2023-05-25 4 FORM 4 SUBMISSION 0001209191-23-032137 5293
2023-05-25 8-K 8-K 5.02,5.07,9.01 0001193125-23-154191 001-36167 23960362 34 171000 1 1
2023-05-05 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-05-05 16:30:00 9999999995-23-001314 333-269846 23895718 33 1715
2023-05-05 4 FORM 4 SUBMISSION 0000899243-23-012353 5437
2023-05-04 10-Q 10-Q 0000950170-23-017483 001-36167 23886612 34 8798434 1 1
2023-05-04 8-K 8-K 2.02,9.01 0001193125-23-135082 001-36167 23886584 34 266725 1 1
2023-05-03 CORRESP filename1.htm 0001193125-23-133252 5900
2023-04-24 4 FORM 4 SUBMISSION 0001209191-23-025464 6607
2023-04-11 ARS ARS 0001193125-23-097204 001-36167 23812416 34 2741250
2023-04-11 DEFA14A DEFA14A 0000950170-23-012369 001-36167 23812405 34 2092783
2023-04-11 DEF 14A DEF 14A 0000950170-23-012367 001-36167 23812398 34 9202823 1 1
2023-04-05 4 FORM 4 SUBMISSION 0001209191-23-023378 4993
2023-03-31 PRE 14A PRE 14A 0000950170-23-011381 001-36167 23787768 34 6356679 1 1
2023-03-10 8-K 8-K 7.01 0001193125-23-067595 001-36167 23723670 34 142500 1 1
2023-03-07 4 FORM 4 SUBMISSION 0001209191-23-016700 4826
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014873 4957
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014872 4908
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014869 7040
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014865 6758
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014861 7004
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014843 6731
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014838 6735
2023-03-01 4 FORM 4 SUBMISSION 0001209191-23-014078 4826
2023-02-21 UPLOAD filename1.pdf 0000000000-23-001718 40258
2023-02-17 4 FORM 4 SUBMISSION 0001209191-23-010509 7948
2023-02-17 S-3 S-3 0001193125-23-041600 333-269846 23640437 33 1529439
2023-02-17 S-8 S-8 0001193125-23-041597 333-269845 23640429 33 77084
2023-02-17 10-K 10-K 0000950170-23-003129 001-36167 23640292 34 21802335 1 1
2023-02-15 8-K 8-K 5.02,9.01 0001193125-23-040183 001-36167 23635324 34 207997 1 1
2023-02-15 8-K 8-K 2.02,9.01 0001193125-23-039757 001-36167 23633635 34 279229 1 1
2023-02-14 SC 13G/A karypharmv2.txt 0001306923-23-000006 005-87705 23629777 34 271759
2023-02-14 SC 13G/A formsc13ga.htm 0001493152-23-004859 005-87705 23628884 34 89490
2023-02-14 SC 13G/A AMENDMENT NO. 8 TO SCHEDULE 13G 0001213900-23-011440 005-87705 23628108 34 212600
2023-02-14 SC 13G/A d9881732_13g-a.htm 0000919574-23-001620 005-87705 23627980 34 181492
2023-02-10 SC 13G SC 13G 0001104659-23-018475 005-87705 23611634 34 83378
2023-02-08 4 FORM 4 SUBMISSION 0001209191-23-007775 4824
2023-02-08 4 FORM 4 SUBMISSION 0001209191-23-007772 4827
2023-02-02 SC 13G/A Karyopharm_Therapeutics_Inc.txt 0000093751-23-000090 005-87705 23579711 34 10364
2023-01-26 SC 13G/A us48576u1060_012623.txt 0001306550-23-004203 005-87705 23554461 34 13403
2023-01-20 SC 13G us48576u1060_012023.txt 0001306550-23-001542 005-87705 23541922 34 13370
2023-01-09 8-K 8-K 2.02,9.01 0001193125-23-004183 001-36167 23516688 34 212315 1 1
2023-01-05 4 FORM 4 SUBMISSION 0001209191-23-002052 4827
2023-01-03 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-01-03 16:30:00 9999999995-23-000026 333-268991 23504255 33 1715
2022-12-29 CORRESP filename1.htm 0001193125-22-314423 6635
2022-12-28 UPLOAD filename1.pdf 0000000000-22-013952 40221
2022-12-23 S-3 S-3 0001193125-22-311793 333-268991 221485529 33 1066612
2022-12-14 8-K 8-K 8.01 0001193125-22-303934 001-36167 221460598 34 150967 1 1
2022-12-08 D xslFormDX01/primary_doc.xml 06b 0001503802-22-000001 021-466961 221452478 33 21211
2022-12-08 SC 13G d9881732_13g.htm 0000919574-22-007017 005-87705 221451623 34 184312
2022-12-06 4 FORM 4 SUBMISSION 0001209191-22-060041 4828
2022-12-05 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-22-298052 001-36167 221443841 34 703834 1 1
2022-12-02 8-K 8-K 5.03,9.01 0001193125-22-297530 001-36167 221441961 34 314777 1 1
2022-11-08 4 FORM 4 SUBMISSION 0001209191-22-056152 4828
2022-11-03 10-Q 10-Q 0000950170-22-021917 001-36167 221358477 34 9862941 1 1
2022-11-03 8-K 8-K 2.02,9.01 0001193125-22-276891 001-36167 221358095 34 265800 1 1
2022-10-05 4 FORM 4 SUBMISSION 0001209191-22-052726 4828
2022-09-09 4 FORM 4 SUBMISSION 0001209191-22-049255 6390
2022-09-01 4 FORM 4 SUBMISSION 0001209191-22-048397 7470
2022-09-01 4 FORM 4 SUBMISSION 0001209191-22-048396 7442
2022-09-01 4 FORM 4 SUBMISSION 0001209191-22-048395 7483
2022-09-01 4 FORM 4 SUBMISSION 0001209191-22-048394 7415
2022-08-19 3 FORM 3 SUBMISSION 0001209191-22-046824 11016
2022-08-15 4 FORM 4 SUBMISSION 0001209191-22-045718 6950
2022-08-05 4 FORM 4 SUBMISSION 0001209191-22-044561 4828
2022-08-04 10-Q 10-Q 0000950170-22-014788 001-36167 221137093 34 10246569 1 1
2022-08-04 8-K 8-K 2.02,9.01 0001193125-22-211832 001-36167 221134727 34 278422 1 1
2022-07-28 8-K 8-K 5.02 0001193125-22-204195 001-36167 221112873 34 145260 1 1
2022-07-11 4 FORM 4 SUBMISSION 0001209191-22-041774 4830
2022-06-15 8-K 8-K 1.02 0001193125-22-174750 001-36167 221017828 34 146473 1 1
2022-06-14 4 FORM 4 SUBMISSION 0001209191-22-036812 6442
2022-06-10 4 FORM 4 SUBMISSION 0000899243-22-021957 15098
2022-06-08 4 FORM 4 SUBMISSION 0000899243-22-021477 4830
2022-06-06 4 FORM 4 SUBMISSION 0000899243-22-021234 6378
2022-06-03 S-8 S-8 0001193125-22-166718 333-265386 22992907 33 116039
2022-05-23 8-K 8-K 5.02,5.07,9.01 0001193125-22-157447 001-36167 22951609 34 160830 1 1
2022-05-20 4 FORM 4 SUBMISSION 0001209191-22-030986 5347
2022-05-20 4 FORM 4 SUBMISSION 0001209191-22-030983 5371
2022-05-20 4 FORM 4 SUBMISSION 0001209191-22-030978 5335
2022-05-20 4 FORM 4 SUBMISSION 0001209191-22-030972 5362
2022-05-20 4 FORM 4 SUBMISSION 0001209191-22-030970 5321
2022-05-20 4 FORM 4 SUBMISSION 0001209191-22-030956 5352
2022-05-20 4 FORM 4 SUBMISSION 0001209191-22-030953 5350
2022-05-12 DEFA14A DEFA14A 0001193125-22-148265 001-36167 22916337 34 41616
2022-05-09 SC 13G formsc13g.htm 0001493152-22-012564 005-87705 22905492 34 99375
2022-05-05 4 FORM 4 SUBMISSION 0001209191-22-027344 6393
2022-05-05 10-Q 10-Q 0000950170-22-007564 001-36167 22894091 34 8784461 1 1
2022-05-05 8-K 8-K 2.02,9.01 0001193125-22-141284 001-36167 22894009 34 254996 1 1
2022-05-02 4 FORM 4 SUBMISSION 0001209191-22-026425 7468
2022-04-29 3 FORM 3 SUBMISSION 0001209191-22-026106 7300
2022-04-08 DEFA14A DEFA14A 0001193125-22-099758 001-36167 22815504 34 143102
2022-04-08 DEF 14A DEF 14A 0000950170-22-005492 001-36167 22815434 34 4464818
2022-03-31 4 FORM 4 SUBMISSION 0001209191-22-021755 8154
2022-03-29 8-K 8-K 5.02,9.01 0001193125-22-087458 001-36167 22777476 34 350297 1 1
2022-03-28 8-K 8-K 5.02 0001193125-22-086854 001-36167 22776440 34 141748 1 1
2022-03-02 4 FORM 4 SUBMISSION 0001209191-22-014629 9750

Latest XBRL company facts

One latest value per concept from companyfacts (321 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 22.68M 2026-08-06 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
dei EntityPublicFloat Entity Public Float USD 37.00M 2025-06-30 2025 FY 10-K 2026-02-13 0001193125-26-049397
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 1.62M 2025-01-01 2025-12-31 DEF 14A 2026-04-13 0001503802-26-000023
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.71M 2025-01-01 2025-12-31 DEF 14A 2026-04-13 0001503802-26-000023
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 2.12M 2025-01-01 2025-12-31 DEF 14A 2026-04-13 0001503802-26-000023
ecd PeoTotalCompAmt PeoTotalCompAmt USD 2.32M 2025-01-01 2025-12-31 DEF 14A 2026-04-13 0001503802-26-000023
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 14.43 2025-01-01 2025-12-31 DEF 14A 2026-04-13 0001503802-26-000023
ffd NetFeeAmt NetFeeAmt USD 16,604.15 2026-05-04 S-3 2026-05-04 0001193125-26-204130
ffd TtlFeeAmt TtlFeeAmt USD 16,604.15 2026-05-04 S-3 2026-05-04 0001193125-26-204130
ffd TtlOfferingAmt TtlOfferingAmt USD 400.00M 2026-05-04 S-3 2026-05-04 0001193125-26-204130
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-05-04 S-3 2026-05-04 0001193125-26-204130
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-05-04 S-3 2026-05-04 0001193125-26-204130
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 7.66M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 88,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 78.80M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 5.96M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 5.51M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 41,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 345.17M 2014-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091264
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.52B 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Share-based Payment Arrangement, Decrease for Tax Withholding Obligation USD 39,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD 67.85M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 4.94M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD 12,000 2011-01-01 2011-12-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 239,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 4.94M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current USD 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AllowanceForDoubtfulAccountsReceivableWriteOffs Accounts Receivable, Allowance for Credit Loss, Writeoff USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts USD 4.92M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AreaOfRealEstateProperty Area of Real Estate Property sqft 3,681 2014-11-30 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap Assets Assets USD 111.32M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AssetsCurrent Assets, Current USD 106.38M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 42.73M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 46.17M 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedGain Debt Securities, Available-for-sale, Unrealized Gain USD 68,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Debt Securities, Available-for-sale, Unrealized Loss USD 2,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 179.61M 2019-09-30 2019 Q3 10-Q 2019-11-04 0001193125-19-282510
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 49,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002729
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 7,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002729
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 68.78M 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002729
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value USD 96.62M 2017-12-31 2017 FY 10-K 2018-03-15 0001193125-18-084024
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value USD 63.80M 2019-12-31 2019 FY 10-K 2020-02-26 0001193125-20-049115
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 55.12M 2014-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091264
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 0 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-222827
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 10.13M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 24.21M 2020-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year Securities 0 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year Security 13 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002729
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 56,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap CapitalLeaseObligationsIncurred Lease Obligation Incurred USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 54.98M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 129.21M 2014-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091264
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 19.33M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-15 0001193125-18-084024
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 65.10M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 55.30M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -5.59M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 18.05M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 474,615 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 106.00M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 22.68M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 22.68M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap CommonStockValue Common Stock, Value, Issued USD 14,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -89.44M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 1.30M 2020-05-31 2022 FY 10-K 2023-02-17 0000950170-23-003129
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 5.80M 2017-04-28 2019 Q3 10-Q 2019-11-04 0001193125-19-282510
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 99.69M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-15 0001193125-16-505181
us-gaap ConvertibleDebtFairValueDisclosures Convertible Debt, Fair Value Disclosures USD 104.70M 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap ConvertibleLongTermNotesPayable Convertible Notes Payable, Noncurrent USD 0 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-022765
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 1.01M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-04 0001193125-19-282510
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 750,000 2008-12-22 2014-03-31 2014 Q1 10-Q 2014-05-08 0001104659-14-036479
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 193.20M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent Debt Instrument, Convertible, Carrying Amount of Equity Component USD 67.90M 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price USD/shares 1 2018-10-16 2020 Q3 10-Q 2020-11-02 0001564590-20-049664
us-gaap DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal Debt Instrument, Convertible, If-converted Value in Excess of Principal USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-02 0001564590-20-049664
us-gaap DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Debt Instrument, Convertible, Threshold Consecutive Trading Days Days 5 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-069231
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 22,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007564
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 0 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss USD 0 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 5.63M 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss USD 2,000 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 5.63M 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 2,000 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 9.04M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredRentCreditCurrent Deferred Rent Credit, Current USD 390,000 2018-12-31 2019 FY 10-K 2020-02-26 0001193125-20-049115
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 3.92M 2018-12-31 2019 FY 10-K 2020-02-26 0001193125-20-049115
us-gaap DeferredRevenue Deferred Revenue USD 297,000 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 297,000 2020-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 0 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 0 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 9.04M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 63.12M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2014-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091264
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsForeign Deferred Tax Assets, Operating Loss Carryforwards, Foreign USD 0 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 0 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 2.83M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 312.80M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DeferredTaxExpenseFromStockOptionsExercised Deferred Tax Expense from Stock Options Exercised USD 4.70M 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-16 0001193125-17-084396
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 2.30M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 0.04 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap Depreciation Depreciation USD 9,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 715,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-02 0001564590-20-049664
us-gaap DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) USD 112.42M 2014-09-30 2014 Q3 10-Q 2014-11-10 0001104659-14-078971
us-gaap DueToRelatedPartiesCurrent Due to Related Parties, Current USD 0 2013-12-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -3.51 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.53 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007564
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -3.51 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure 0.537 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.004 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.046 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.026 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent pure 0.002 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.053 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.039 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.139 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations USD 200,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-15 0001193125-18-084024
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD -2,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap EffectOfExchangeRateOnCashContinuingOperations Effect of Exchange Rate on Cash, Continuing Operations USD -11,000 2015-01-01 2015-03-31 2015 Q1 10-Q 2015-05-11 0001193125-15-181874
us-gaap EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Embedded Derivative, Fair Value of Embedded Derivative Liability USD 2.80M 2024-03-31 2024 Q1 10-Q 2024-05-08 0000950170-24-055672
us-gaap EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet Embedded Derivative, Fair Value of Embedded Derivative, Net USD 1.80M 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Embedded Derivative, Gain (Loss) on Embedded Derivative, Net USD -15.55M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 4.38M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap FederalIncomeTaxExpenseBenefitContinuingOperations Federal Income Tax Expense (Benefit), Continuing Operations USD -96.68M 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-15 0001193125-16-505181
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 300,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap ForeignIncomeTaxExpenseBenefitContinuingOperations Foreign Income Tax Expense (Benefit), Continuing Operations USD -21.41M 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-15 0001193125-16-505181
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -50,000 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-16 0001193125-17-084396
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD -62.37M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 51.77M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-07 0001193125-19-215344
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -192.38M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -89.41M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -3.61M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -195.96M 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 1,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD -105.19M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 840,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -41.16M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.08M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -157,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD -27.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 3.66M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 3.69M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 3.51M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003129
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -8.03M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-08 0001193125-18-322696
us-gaap IncreaseDecreaseInDepositOtherAssets Increase (Decrease) in Deposit Assets USD 30,000 2008-12-22 2013-12-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD -44,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD -11.70M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007564
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 19.50M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -1.78M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap IncreaseDecreaseInPrepaidRent Increase (Decrease) in Prepaid Rent USD -2.65M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-24 0001193125-21-054811
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD 82,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-15 0001193125-18-084024
us-gaap IncreaseInRestrictedCash Increase in Restricted Cash USD 400,000 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-10 0001104659-14-078971
us-gaap InterestExpense Interest Expense USD 14.83M 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-06 0000950170-24-091210
us-gaap InterestExpenseLongTermDebt Interest Expense, Long-term Debt USD 11.30M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 25.70M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InterestPayableCurrent Interest Payable, Current USD 10.34M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap InterestPayableCurrentAndNoncurrent Interest Payable USD 23.91M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap InventoryFinishedGoods Inventory, Finished Goods, Gross USD 199,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InventoryNet Inventory, Net USD 3.99M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InventoryRawMaterialsAndSupplies Inventory, Raw Materials and Supplies, Gross USD 628,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InventoryValuationReserves Inventory Valuation Reserves USD 400,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002729
us-gaap InventoryWorkInProcess Inventory, Work in Process, Gross USD 3.17M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InventoryWorkInProcessAndRawMaterialsNetOfReserves Inventory, Work in Process and Raw Materials, Net of Reserves USD 1.57M 2020-09-30 2020 Q3 10-Q 2020-11-02 0001564590-20-049664
us-gaap InventoryWriteDown Inventory Write-down USD 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007564
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 1.23M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap InvestmentsFairValueDisclosure Investments, Fair Value Disclosure USD 231.36M 2015-06-30 2015 Q2 10-Q 2015-08-10 0001193125-15-283822
us-gaap LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate pure 0.145 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 9.39M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 1.56M 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-022765
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 1.88M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 1.56M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 2.04M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 1.99M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 1.93M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 793,000 2019-09-30 2019 Q3 10-Q 2019-11-04 0001193125-19-282510
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 2.68M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap Liabilities Liabilities USD 441.49M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 111.32M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap LiabilitiesCurrent Liabilities, Current USD 134.23M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap LicenseAndServicesRevenue License and Services Revenue (Deprecated 2018-01-31) USD 10.00M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap LongTermDebt Long-term Debt USD 169.29M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 5.17M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 177.68M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 5.17M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 5.17M 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap LongTermInvestments Long-term Investments USD 10.31M 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap MarketableSecuritiesGainLoss Marketable Securities, Gain (Loss) USD 2,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007564
us-gaap NetCashProvidedByUsedInContinuingOperations Net Cash Provided by (Used in) Continuing Operations USD -5.37M 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091264
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 48.90M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 429,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -6.84M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 2.48M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -47.66M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -34.65M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -89.42M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -13.57M 2024-01-01 2024-06-30 2025 Q2 10-Q 2025-08-11 0000950170-25-106238
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -30.55M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-222827
us-gaap NoncashOrPartNoncashAcquisitionPayablesAssumed1 Noncash or Part Noncash Acquisition, Payables Assumed USD 52,000 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-16 0001193125-17-084396
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -40.13M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap NotesIssued1 Notes Issued USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OperatingCostsAndExpenses Operating Costs and Expenses USD 1.43M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007564
us-gaap OperatingExpenses Operating Expenses USD 117.78M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -49.29M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.80M 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003129
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 2.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 6.71M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.07M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 5.18M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 4.26M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 23.43M 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 3.05M 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 3.72M 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 3.45M 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 3.28M 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 3.21M 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 6.74M 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OperatingLeasesRentExpenseContingentRentals Operating Leases, Rent Expense, Contingent Rentals USD 898,000 2014-03-01 2014-03-31 2014 Q3 10-Q 2014-11-10 0001104659-14-078971
us-gaap OperatingLeasesRentExpenseMinimumRentals Operating Leases, Rent Expense, Minimum Rentals USD 506,000 2014-03-01 2014-03-31 2014 Q3 10-Q 2014-11-10 0001104659-14-078971
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 2.48M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 4.61M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap OtherAssets Other Assets USD 267,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OtherAssetsCurrent Other Assets, Current USD 31.47M 2022-09-30 2022 Q3 10-Q 2022-11-03 0000950170-22-021917
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 15,000 2017-03-31 2017 Q1 10-Q 2017-05-04 0001193125-17-158670
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD -25,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -5,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OtherIncome Other Income USD 6.00M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-29 0000950170-24-022650
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 6.39M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 336,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-08 0000950170-24-055672
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 7,000 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-10 0001193125-15-283822
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -15.66M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 188,000 2008-12-22 2014-03-31 2014 Q1 10-Q 2014-05-08 0001104659-14-036479
us-gaap ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic Participating Securities, Distributed and Undistributed Earnings (Loss), Basic USD 0 2024-01-01 2024-06-30 2025 Q2 10-Q 2025-08-11 0000950170-25-106238
us-gaap PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs USD 1.90M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PaymentsForProceedsFromInvestments Payments for (Proceeds from) Investments USD 63.80M 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091264
us-gaap PaymentsForRoyalties Payments for Royalties USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-03 0001193125-25-261667
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 427,000 2014-01-01 2014-06-30 2015 Q2 10-Q 2015-08-10 0001193125-15-283822
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 39,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 10.04M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PaymentsToAcquireInProcessResearchAndDevelopment Payments to Acquire in Process Research and Development USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-29 0000950170-24-022650
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 24.74M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 7.41M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 10.05M 2022-09-30 2022 Q3 10-Q 2022-11-03 0000950170-22-021917
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 15.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 166.88M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 113.20M 2013-12-01 2013-12-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 20.23M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 2.00M 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091264
us-gaap ProceedsFromIssuanceOfSecuredDebt Proceeds from Issuance of Secured Debt USD 12.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 574,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 3.20M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments Proceeds from Sale, Maturity and Collection of Investments USD 27.60M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 0 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-04 0000950170-23-017483
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -89.42M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 5.61M 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 94,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ReceivablesNetCurrent Receivables, Net, Current USD 29.87M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party USD 1.42M 2008-12-22 2013-12-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap RepaymentsOfConvertibleDebt Repayments of Convertible Debt USD 250,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 62.75M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003129
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 0 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 318,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.85B 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 68.50M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 20.00M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap RevenueFromGrants Revenue from Grants (Deprecated 2018-01-31) USD 71,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-02 0001564590-17-021223
us-gaap RevenueRecognitionMilestoneMethodRevenueRecognized Revenue Recognition, Milestone Method, Revenue Recognized USD 21.92M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-15 0001193125-18-084024
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 11.71M 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-01 0000950170-22-002548
us-gaap SalesRevenueNet Revenue, Net (Deprecated 2018-01-31) USD 68,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-04 0001193125-17-158670
us-gaap SecuredDebtCurrent Secured Debt, Current USD 40.31M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap SecuredLongTermDebt Secured Long-term Debt, Noncurrent USD 85.05M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap SecurityDeposit Security Deposit USD 200,000 2018-01-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap SellingGeneralAndAdministrativeExpense Selling, General and Administrative Expense USD 52.60M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 4.94M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 1.96M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-28 0001193125-19-057610
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized shares 1.68M 2017-12-31 2017 FY 10-K 2018-03-15 0001193125-18-084024
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 5.74M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 59.06 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap SharePrice Share Price USD/shares 42.5 2014-07-31 2014 Q3 10-Q 2014-11-10 0001104659-14-078971
us-gaap ShortTermInvestments Short-term Investments USD 93.42M 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159200
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -330.17M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.303 2013-10-01 2013-10-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap StockIssued1 Stock Issued USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Stock Issued During Period, Shares, Conversion of Convertible Securities shares 3.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 46,815 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-16 0001193125-17-084396
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 2.45M 2014-07-01 2014-07-31 2014 Q3 10-Q 2014-11-10 0001104659-14-078971
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 397,087 2014-07-01 2014-07-31 2014 Q3 10-Q 2014-11-10 0001104659-14-078971
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 340,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-16 0001193125-17-084396
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 189.76M 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-19 0000950170-25-022765
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 6.93M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap StockIssuedDuringPeriodValuePurchaseOfAssets Stock Issued During Period, Value, Purchase of Assets USD 1.35M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-29 0000950170-24-022650
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 0 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-05 0000950170-21-000948
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 574,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 18.28M 2012-12-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2013-12-31 2013 FY 10-K 2014-03-21 0001047469-14-002800
us-gaap TenantImprovements Tenant Improvements USD 1.62M 2015-03-31 2017 FY 10-K 2018-03-15 0001193125-18-084024
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 133.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-13 0001193125-26-049397
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 25,495 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 77.57M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007564
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 25,495 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347906

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →